Immunocore (NASDAQ:IMCR – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $100.00 price target on the stock. HC Wainwright‘s target price would suggest a potential upside of 221.43% from the stock’s current price.
Several other equities analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Mizuho increased their price objective on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Thursday, October 15th. Finally, JPMorgan Chase & Co. initiated coverage on Immunocore in a report on Friday, August 21st. They set an “overweight” rating and a $50.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.38.
Get Our Latest Stock Analysis on IMCR
Immunocore Trading Up 0.4%
NASDAQ:IMCR traded up $0.13 on Monday, reaching $31.11. 72,455 shares of the company’s stock were exchanged, compared to its average volume of 457,274. The business has a fifty day moving average of $32.82 and a 200-day moving average of $31.66. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94. Immunocore has a 52-week low of $27.50 and a 52-week high of $40.71. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -84.08 and a beta of 0.81.
Immunocore (NASDAQ:IMCR – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. As a group, analysts expect that Immunocore will post 0.04 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in IMCR. Engineers Gate Manager LP increased its position in Immunocore by 334.3% during the 2nd quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock worth $1,915,000 after purchasing an additional 46,435 shares in the last quarter. Braidwell LP purchased a new stake in Immunocore during the 2nd quarter worth about $16,552,000. Eversept Partners LP purchased a new stake in Immunocore during the 1st quarter worth about $1,183,000. Public Employees Retirement System of Ohio purchased a new stake in Immunocore during the 2nd quarter worth about $2,145,000. Finally, Stempoint Capital LP purchased a new stake in Immunocore during the 1st quarter worth about $1,916,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.
Immunocore Company Profile
Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.
The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.
See Also
- Five stocks we like better than Immunocore
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
